SUPPLEMENT

Q2 2020 — Sales of Key Products/Franchises

Q2 2020PDF · 4 pages214 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
BABY CARE
US 	96	$ 	99 	-3.5% 	-3.5% 	- 	188	$ 	186 	1.2% 	1.2% 	-
Intl 	260 	344 	-24.3% 	-16.6% 	-7.7% 	529 	651 	-18.7% 	-12.6% 	-6.1%
WW 	356 	443 	-19.7% 	-13.6% 	-6.1% 	717 	837 	-14.3% 	-9.5% 	-4.8%
ORAL CARE
US 	170 	155 	9.7% 	9.7% 	- 	346 	306 	12.9% 	12.9% 	-
Intl 	227 	234 	-2.8% 	4.0% 	-6.8% 	446 	450 	-0.8% 	4.6% 	-5.4%
WW 	397 	389 	2.2% 	6.3% 	-4.1% 	792 	756 	4.8% 	8.0% 	-3.2%
OTC
US 	627 	484 	29.6% 	29.6% 	- 	1,316 	991 	32.8% 	32.8% 	-
Intl 	522 	580 	-10.1% 	-5.0% 	-5.1% 	1,181 	1,160 	1.8% 	6.0% 	-4.2%
WW 	1,149 	1,064 	7.9% 	10.7% 	-2.8% 	2,497 	2,151 	16.1% 	18.3% 	-2.2%
SKIN HEALTH / BEAUTY(4)
US 	536 	663 	-19.2% 	-19.2% 	- 	1,195 	1,251 	-4.5% 	-4.5% 	-
Intl 	471 	539 	-12.5% 	-8.2% 	-4.3% 	929 	1,041 	-10.7% 	-7.4% 	-3.3%
WW 	1,007 	1,202 	-16.2% 	-14.3% 	-1.9% 	2,124 	2,292 	-7.3% 	-5.8% 	-1.5%
WOMEN'S HEALTH
US 	3 	3 	-2.9% 	-2.9% 	- 	7 	6 	14.3% 	14.3% 	-
Intl 	199 	250 	-20.4% 	-12.0% 	-8.4% 	427 	472 	-9.6% 	-2.1% 	-7.5%
WW 	202 	253 	-20.1% 	-11.8% 	-8.3% 	434 	478 	-9.3% 	-1.9% 	-7.4%
WOUND CARE / OTHER
US 	126 	132 	-4.7% 	-4.7% 	- 	245 	234 	4.7% 	4.7% 	-
Intl 	59 	61 	-2.4% 	3.7% 	-6.1% 	111 	114 	-1.9% 	2.8% 	-4.7%
WW 	185 	193 	-4.0% 	-2.1% 	-1.9% 	356 	348 	2.6% 	4.1% 	-1.5%
TOTAL CONSUMER HEALTH
US 	1,557 	1,537 	1.3% 	1.3% 	- 	3,297 	2,975 	10.8% 	10.8% 	-
Intl 	1,739 	2,007 	-13.4% 	-7.4% 	-6.0% 	3,624 	3,887 	-6.8% 	-1.9% 	-4.9%
WW 	3,296	$ 	3,544 	-7.0% 	-3.6% 	-3.4% 	6,921	$ 	6,862 	0.9% 	3.6% 	-2.7%
See footnotes at end of schedule
% Change 	% Change

-- 1 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,362	$ 	2,379 	-0.7% 	-0.7% 	- 	4,772	$ 	4,542 	5.1% 	5.1% 	-
Intl 	1,161 	1,087 	6.8% 	11.0% 	-4.2% 	2,389 	2,175 	9.8% 	13.7% 	-3.9%
WW 	3,523 	3,466 	1.6% 	3.0% 	-1.4% 	7,161 	6,717 	6.6% 	7.9% 	-1.3%
REMICADE
US 	593 	801 	-25.8% 	-25.8% 	- 	1,218 	1,575 	-22.7% 	-22.7% 	-
US Exports (6) 133 	62 	* 	* 	- 	243 	138 	75.7% 	75.7% 	-
Intl 	208 	244 	-14.5% 	-8.7% 	-5.8% 	464 	496 	-6.4% 	-1.6% 	-4.8%
WW 	935 	1,107 	-15.5% 	-14.2% 	-1.3% 	1,925 	2,209 	-12.9% 	-11.8% 	-1.1%
SIMPONI / SIMPONI ARIA
US 	256 	281 	-8.7% 	-8.7% 	- 	528 	544 	-2.9% 	-2.9% 	-
Intl 	289 	282 	2.6% 	6.8% 	-4.2% 	547 	543 	0.8% 	4.8% 	-4.0%
WW 	546 	563 	-3.0% 	-0.9% 	-2.1% 	1,075 	1,087 	-1.1% 	1.0% 	-2.1%
STELARA
US 	1,138 	1,058 	7.5% 	7.5% 	- 	2,355 	1,940 	21.4% 	21.4% 	-
Intl 	558 	499 	11.9% 	15.5% 	-3.6% 	1,161 	1,022 	13.6% 	16.9% 	-3.3%
WW 	1,697 	1,558 	8.9% 	10.1% 	-1.2% 	3,516 	2,963 	18.7% 	19.8% 	-1.1%
TREMFYA
US 	241 	176 	36.7% 	36.7% 	- 	428 	344 	24.4% 	24.4% 	-
Intl 	101 	59 	71.0% 	73.4% 	-2.4% 	210 	108 	94.0% 	97.1% 	-3.1%
WW 	342 	235 	45.4% 	46.0% 	-0.6% 	638 	452 	41.1% 	41.8% 	-0.7%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	3 	3 	11.8% 	21.6% 	-9.8% 	6 	6 	2.7% 	8.4% 	-5.7%
WW 	3 	3 	11.8% 	21.6% 	-9.8% 	6 	6 	2.7% 	8.4% 	-5.7%
INFECTIOUS DISEASES
US 	416 	387 	7.4% 	7.4% 	- 	852 	744 	14.5% 	14.5% 	-
Intl 	463 	475 	-2.5% 	2.6% 	-5.1% 	946 	964 	-1.8% 	2.7% 	-4.5%
WW 	878 	862 	1.9% 	4.7% 	-2.8% 	1,798 	1,708 	5.3% 	7.8% 	-2.5%
EDURANT / rilpivirine
US 	10 	12 	-14.0% 	-14.0% 	- 	22 	24 	-6.9% 	-6.9% 	-
Intl 	246 	198 	24.5% 	27.7% 	-3.2% 	458 	397 	15.4% 	18.4% 	-3.0%
WW 	256 	210 	22.2% 	25.2% 	-3.0% 	480 	421 	14.1% 	17.0% 	-2.9%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	379 	344 	10.5% 	10.5% 	- 	775 	659 	17.7% 	17.7% 	-
Intl 	130 	191 	-32.0% 	-26.1% 	-5.9% 	314 	399 	-21.4% 	-15.8% 	-5.6%
WW 	510 	535 	-4.7% 	-2.6% 	-2.1% 	1,089 	1,058 	2.9% 	5.0% 	-2.1%
OTHER INFECTIOUS DISEASES
US 	25 	31 	-18.7% 	-18.7% 	- 	54 	61 	-11.2% 	-11.2% 	-
Intl 	87 	86 	1.0% 	8.7% 	-7.7% 	174 	168 	3.8% 	9.4% 	-5.6%
WW 	113 	117 	-4.2% 	1.5% 	-5.7% 	229 	229 	-0.2% 	3.9% 	-4.1%
% Change 	% Change

-- 2 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	778 	664 	17.4% 	17.4% 	- 	1,526 	1,387 	10.1% 	10.1% 	-
Intl 	809 	875 	-7.6% 	-4.1% 	-3.5% 	1,719 	1,780 	-3.5% 	-0.5% 	-3.0%
WW 	1,587 	1,538 	3.2% 	5.2% 	-2.0% 	3,245 	3,167 	2.5% 	4.1% 	-1.6%
CONCERTA / Methylphenidate
US 	55 	15 	* 	* 	- 	107 	112 	-4.2% 	-4.2% 	-
Intl 	94 	123 	-23.0% 	-20.2% 	-2.8% 	212 	239 	-11.0% 	-8.6% 	-2.4%
WW 	149 	137 	8.7% 	11.2% 	-2.5% 	320 	351 	-8.9% 	-7.2% 	-1.7%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	576 	506 	13.8% 	13.8% 	- 	1,120 	989 	13.2% 	13.2% 	-
Intl 	303 	312 	-2.8% 	0.3% 	-3.1% 	642 	619 	3.7% 	6.7% 	-3.0%
WW 	879 	818 	7.5% 	8.6% 	-1.1% 	1,762 	1,608 	9.5% 	10.7% 	-1.2%
RISPERDAL CONSTA
US 	74 	81 	-9.3% 	-9.3% 	- 	150 	158 	-4.9% 	-4.9% 	-
Intl 	79 	101 	-21.2% 	-18.1% 	-3.1% 	173 	203 	-14.9% 	-11.9% 	-3.0%
WW 	153 	182 	-15.9% 	-14.2% 	-1.7% 	323 	361 	-10.5% 	-8.9% 	-1.6%
OTHER NEUROSCIENCE
US 	75 	62 	21.5% 	21.5% 	- 	150 	128 	16.8% 	16.8% 	-
Intl 	331 	340 	-2.5% 	1.7% 	-4.2% 	691 	719 	-3.9% 	-0.8% 	-3.1%
WW 	406 	401 	1.2% 	4.7% 	-3.5% 	841 	847 	-0.7% 	1.8% 	-2.5%
ONCOLOGY
US 	1,181 	1,013 	16.6% 	16.6% 	- 	2,356 	1,975 	19.3% 	19.3% 	-
Intl 	1,609 	1,684 	-4.4% 	-0.9% 	-3.5% 	3,448 	3,240 	6.4% 	9.9% 	-3.5%
WW 	2,791 	2,697 	3.5% 	5.7% 	-2.2% 	5,804 	5,215 	11.3% 	13.5% 	-2.2%
DARZALEX
US 	492 	369 	32.9% 	32.9% 	- 	955 	721 	32.3% 	32.3% 	-
Intl 	409 	405 	1.2% 	5.9% 	-4.7% 	883 	682 	29.6% 	34.7% 	-5.1%
WW 	901 	774 	16.3% 	18.8% 	-2.5% 	1,838 	1,403 	31.0% 	33.5% 	-2.5%
ERLEADA
US 	136 	62 	* 	* 	- 	255 	120 	* 	* 	-
Intl 	33 	7 	* 	* 	* 	57 	10 	* 	* 	*
WW 	170 	69 	* 	* 	* 	313 	130 	* 	* 	*
IMBRUVICA
US 	447 	367 	21.5% 	21.5% 	- 	879 	716 	22.6% 	22.6% 	-
Intl 	502 	463 	8.3% 	13.4% 	-5.1% 	1,101 	898 	22.6% 	27.4% 	-4.8%
WW 	949 	831 	14.1% 	17.0% 	-2.9% 	1,980 	1,615 	22.6% 	25.3% 	-2.7%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	98 	224 	-56.1% 	-55.2% 	-0.9% 	206 	487 	-57.7% 	-56.9% 	-0.8%
WW 	98 	224 	-56.1% 	-55.2% 	-0.9% 	206 	487 	-57.7% 	-56.9% 	-0.8%
ZYTIGA / abiraterone acetate
US 	87 	198 	-55.6% 	-55.6% 	- 	226 	383 	-40.9% 	-40.9% 	-
Intl 	480 	500 	-3.9% 	-2.0% 	-1.9% 	1,032 	994 	3.8% 	6.1% 	-2.3%
WW 	568 	698 	-18.6% 	-17.2% 	-1.4% 	1,258 	1,377 	-8.6% 	-7.0% 	-1.6%
OTHER ONCOLOGY
US 	20 	16 	22.9% 	22.9% 	- 	42 	34 	21.4% 	21.4% 	-
Intl 	87 	85 	2.2% 	5.9% 	-3.7% 	169 	169 	-0.3% 	3.3% 	-3.6%
WW 	106 	101 	5.5% 	8.6% 	-3.1% 	210 	203 	3.4% 	6.3% 	-2.9%
PULMONARY HYPERTENSION
US 	545 	439 	24.2% 	24.2% 	- 	1,031 	869 	18.7% 	18.7% 	-
Intl 	243 	251 	-3.3% 	-1.0% 	-2.3% 	503 	477 	5.3% 	7.9% 	-2.6%
WW 	789 	690 	14.2% 	15.0% 	-0.8% 	1,534 	1,346 	13.9% 	14.9% 	-1.0%
OPSUMIT
US 	256 	203 	26.1% 	26.1% 	- 	485 	375 	29.3% 	29.3% 	-
Intl 	150 	146 	3.0% 	5.7% 	-2.7% 	310 	279 	11.2% 	14.1% 	-2.9%
WW 	406 	348 	16.5% 	17.6% 	-1.1% 	795 	654 	21.6% 	22.8% 	-1.2%
UPTRAVI
US 	254 	175 	44.5% 	44.5% 	- 	466 	351 	32.6% 	32.6% 	-
Intl 	28 	28 	4.0% 	7.3% 	-3.3% 	66 	50 	33.6% 	37.6% 	-4.0%
WW 	282 	203 	39.0% 	39.5% 	-0.5% 	532 	401 	32.7% 	33.2% 	-0.5%
OTHER PULMONARY HYPERTENSION
US 	37 	61 	-40.2% 	-40.2% 	- 	81 	143 	-43.5% 	-43.5% 	-
Intl 	64 	78 	-17.6% 	-16.4% 	-1.2% 	126 	149 	-15.1% 	-13.7% 	-1.4%
WW 	101 	140 	-27.5% 	-26.9% 	-0.6% 	207 	292 	-29.0% 	-28.3% 	-0.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	837 	902 	-7.2% 	-7.2% 	- 	1,643 	1,849 	-11.1% 	-11.1% 	-
Intl 	347 	373 	-7.0% 	-2.4% 	-4.6% 	701 	771 	-9.1% 	-5.6% 	-3.5%
WW 	1,184 	1,275 	-7.1% 	-5.8% 	-1.3% 	2,344 	2,620 	-10.5% 	-9.5% 	-1.0%
XARELTO
US 	559 	549 	1.7% 	1.7% 	- 	1,086 	1,091 	-0.5% 	-0.5% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	559 	549 	1.7% 	1.7% 	- 	1,086 	1,091 	-0.5% 	-0.5% 	-
INVOKANA / INVOKAMET
US 	132 	132 	-0.8% 	-0.8% 	- 	249 	286 	-13.0% 	-13.0% 	-
Intl 	47 	43 	9.1% 	14.8% 	-5.7% 	105 	92 	14.1% 	18.1% 	-4.0%
WW 	179 	177 	1.6% 	3.1% 	-1.5% 	354 	379 	-6.4% 	-5.5% 	-0.9%
PROCRIT / EPREX
US 	70 	113 	-38.3% 	-38.3% 	- 	146 	261 	-44.1% 	-44.1% 	-
Intl 	66 	70 	-5.0% 	-2.3% 	-2.7% 	145 	148 	-2.2% 	-0.1% 	-2.1%
WW 	136 	183 	-25.6% 	-24.6% 	-1.0% 	291 	409 	-28.9% 	-28.2% 	-0.7%
OTHER
US 	78 	107 	-27.7% 	-27.7% 	- 	163 	211 	-22.9% 	-22.9% 	-
Intl 	234 	260 	-10.2% 	-5.3% 	-4.9% 	451 	531 	-15.0% 	-11.3% 	-3.7%
WW 	312 	368 	-15.3% 	-11.8% 	-3.5% 	614 	742 	-17.3% 	-14.6% 	-2.7%
TOTAL PHARMACEUTICAL
US 	6,120 	5,783 	5.8% 	5.8% 	- 	12,181 	11,365 	7.2% 	7.2% 	-
Intl 	4,632 	4,746 	-2.4% 	1.4% 	-3.8% 	9,705 	9,408 	3.2% 	6.7% 	-3.5%
WW 	10,752	$ 	10,529 	2.1% 	3.9% 	-1.8% 	21,886	$ 	20,773 	5.4% 	7.0% 	-1.6%
See footnotes at end of schedule
% Change 	% Change

-- 3 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	255 	366 	-30.5% 	-30.5% 	- 	620 	709 	-12.6% 	-12.6% 	-
Intl 	335 	385 	-12.8% 	-10.9% 	-1.9% 	697 	774 	-9.9% 	-8.0% 	-1.9%
WW 	590 	750 	-21.5% 	-20.5% 	-1.0% 	1,317 	1,482 	-11.2% 	-10.2% 	-1.0%
ORTHOPAEDICS
US 	869 	1,331 	-34.7% 	-34.7% 	- 	2,119 	2,649 	-20.0% 	-20.0% 	-
Intl 	583 	894 	-34.8% 	-32.6% 	-2.2% 	1,371 	1,779 	-22.9% 	-20.6% 	-2.3%
WW 	1,451 	2,224 	-34.7% 	-33.9% 	-0.8% 	3,489 	4,428 	-21.2% 	-20.3% 	-0.9%
HIPS
US 	137 	216 	-36.5% 	-36.5% 	- 	343 	429 	-20.1% 	-20.1% 	-
Intl 	88 	147 	-39.8% 	-37.3% 	-2.5% 	220 	295 	-25.4% 	-22.8% 	-2.6%
WW 	226 	364 	-37.8% 	-36.8% 	-1.0% 	563 	725 	-22.3% 	-21.2% 	-1.1%
KNEES
US 	108 	218 	-50.5% 	-50.5% 	- 	322 	441 	-27.1% 	-27.1% 	-
Intl 	66 	153 	-56.8% 	-55.3% 	-1.5% 	196 	299 	-34.6% 	-32.7% 	-1.9%
WW 	174 	372 	-53.1% 	-52.5% 	-0.6% 	517 	741 	-30.1% 	-29.3% 	-0.8%
TRAUMA
US 	354 	407 	-12.9% 	-12.9% 	- 	761 	824 	-7.6% 	-7.6% 	-
Intl 	198 	265 	-25.2% 	-22.6% 	-2.6% 	445 	533 	-16.5% 	-13.9% 	-2.6%
WW 	553 	672 	-17.8% 	-16.7% 	-1.1% 	1,207 	1,357 	-11.1% 	-10.0% 	-1.1%
SPINE, SPORTS & OTHER
(7)
US 	270 	490 	-45.0% 	-45.0% 	- 	693 	955 	-27.4% 	-27.4% 	-
Intl 	230 	328 	-29.9% 	-27.9% 	-2.0% 	510 	651 	-21.7% 	-19.6% 	-2.1%
WW 	499 	818 	-39.0% 	-38.2% 	-0.8% 	1,202 	1,606 	-25.1% 	-24.3% 	-0.8%
SURGERY
US 	490 	926 	-47.0% 	-47.0% 	- 	1,334 	1,927 	-30.8% 	-30.8% 	-
Intl 	1,060 	1,427 	-25.7% 	-22.6% 	-3.1% 	2,317 	2,821 	-17.9% 	-14.8% 	-3.1%
WW 	1,551 	2,353 	-34.1% 	-32.2% 	-1.9% 	3,651 	4,748 	-23.1% 	-21.3% 	-1.8%
ADVANCED
US 	277 	396 	-30.0% 	-30.0% 	- 	658 	800 	-17.7% 	-17.7% 	-
Intl 	498 	633 	-21.2% 	-18.4% 	-2.8% 	1,065 	1,209 	-11.9% 	-8.9% 	-3.0%
WW 	775 	1,029 	-24.6% 	-22.9% 	-1.7% 	1,723 	2,009 	-14.2% 	-12.4% 	-1.8%
GENERAL
US 	213 	530 	-59.8% 	-59.8% 	- 	676 	1,127 	-40.0% 	-40.0% 	-
Intl 	562 	794 	-29.2% 	-26.0% 	-3.2% 	1,252 	1,612 	-22.4% 	-19.2% 	-3.2%
WW 	775 	1,325 	-41.5% 	-39.5% 	-2.0% 	1,928 	2,739 	-29.6% 	-27.8% 	-1.8%
VISION
US 	248 	461 	-46.1% 	-46.1% 	- 	687 	907 	-24.2% 	-24.2% 	-
Intl 	447 	701 	-36.1% 	-34.8% 	-1.3% 	1,075 	1,383 	-22.3% 	-20.8% 	-1.5%
WW 	695 	1,161 	-40.1% 	-39.3% 	-0.8% 	1,762 	2,290 	-23.0% 	-22.2% 	-0.8%
CONTACT LENSES / OTHER
US 	203 	333 	-39.0% 	-39.0% 	- 	549 	654 	-16.1% 	-16.1% 	-
Intl 	352 	509 	-30.9% 	-29.6% 	-1.3% 	819 	1,011 	-19.0% 	-17.6% 	-1.4%
WW 	554 	842 	-34.1% 	-33.3% 	-0.8% 	1,368 	1,666 	-17.9% 	-17.0% 	-0.9%
SURGICAL
US 	45 	128 	-64.6% 	-64.6% 	- 	138 	253 	-45.3% 	-45.3% 	-
Intl 	96 	191 	-49.9% 	-48.8% 	-1.1% 	256 	371 	-31.0% 	-29.6% 	-1.4%
WW 	141 	319 	-55.8% 	-55.2% 	-0.6% 	394 	624 	-36.8% 	-36.0% 	-0.8%
TOTAL MEDICAL DEVICES
US 	1,862 	3,083 	-39.6% 	-39.6% 	- 	4,760 	6,192 	-23.1% 	-23.1% 	-
Intl 	2,426 	3,406 	-28.8% 	-26.4% 	-2.4% 	5,460 	6,756 	-19.2% 	-16.8% 	-2.4%
WW 	4,288	$ 	6,489 	-33.9% 	-32.7% 	-1.2% 	10,220	$ 	12,948 	-21.1% 	-19.8% 	-1.3%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 4 of 4 --